Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
ally bridge group
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
big data analytics
blackrock
bluebird bio
casdin capital
diabetic nephropathy
duchenne muscular dystrophy
dyne therapeutics
eventide asset management
facioscapulohumeral muscular dystrophy
focal segmental glomerulosclerosis
gene therapy
goldfinch bio
irving investors
jay ghosh
joshua brumm
kaleido biosciences
muscular dystrophy
myotonic dystrophy type 1
new york blog main
rare disease drugs
romesh subramanian
san diego blog main
san francisco blog main
schroeder adveq
software
susanna high
third rock ventures
What
diseases
2
×
drug
genetic
ipo
2
×
medicines
ago
analysis
bio
biotech
biotechs
bring
company
considering
data
develop
dyne
early
employing
expected
experimental
eyes
goldfinch
having
humans
ipos
kidney
later
lead
long
million
muscle
new
raised
raises
rare
reach
studies
therapeutics
worked
Language
unset
Current search:
ipo
×
diseases
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
